Apixaban is a potent, selective, and reversible oral anticoagulant belonging to the class of direct Factor Xa inhibitors. It is formulated and marketed by Kureasia Pharma in tablet form in two strengths—2.5 mg and 5 mg—each film-coated for easy swallowing and consistent absorption. The active ingredient, Apixaban, acts by directly inhibiting Factor Xa, a key enzyme in the coagulation cascade responsible for the conversion of prothrombin to thrombin. Through this mechanism, Apixaban effectively prevents the formation of fibrin clots and reduces the risk of thrombosis, offering targeted anticoagulation with predictable pharmacological effects.
Each Apixaban 2.5 mg or 5 mg tablet contains the active substance Apixaban along with pharmaceutical excipients that aid stability and bioavailability. The tablets are designed for oral administration and can be taken with or without food. The 2.5 mg tablets are typically yellow, while the 5 mg tablets are red, both film-coated, round, and biconvex in shape. The formulation ensures rapid and consistent absorption, with peak plasma concentrations achieved approximately 3 to 4 hours after ingestion. Apixaban exhibits about 50% bioavailability, high plasma protein binding (~87%), and a mean half-life of about 12 hours, allowing for convenient twice-daily dosing.
Apixaban works by selectively blocking both free and clot-bound Factor Xa and prothrombinase activity, thereby preventing thrombin generation and subsequent thrombus development. Unlike vitamin K antagonists (e.g., warfarin), Apixaban does not affect platelet aggregation directly and does not require routine coagulation monitoring. Its pharmacokinetic properties are consistent and predictable, making it a preferred agent for long-term anticoagulation therapy.
Kureasia Pharma Apixaban is indicated for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF), treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prophylaxis of venous thromboembolism (VTE) in adult patients undergoing major orthopedic surgeries such as hip or knee replacement. It is also used for the prevention of recurrent DVT and PE following initial therapy.
The recommended dosage depends on the indication and patient’s clinical profile. Commonly, 5 mg twice daily is used for most adults, while a reduced dose of 2.5 mg twice daily is advised for patients with specific risk factors such as advanced age, low body weight, or impaired renal function. The onset of action is rapid, and the anticoagulant effect is reversible upon discontinuation, allowing flexible management around surgical or invasive procedures.
Apixaban demonstrates a favorable safety profile with a lower risk of major bleeding compared to traditional anticoagulants. Nonetheless, as with all anticoagulants, bleeding is the most significant adverse effect. Other possible side effects may include anemia, nausea, or minor bruising. Apixaban is metabolized primarily by CYP3A4 and transported by P-glycoprotein, hence caution is advised when co-administered with strong inhibitors or inducers of these pathways.
Kureasia Pharma manufactures Apixaban tablets under strict Good Manufacturing Practices (GMP) to ensure high purity, consistent potency, and reliable therapeutic performance. The product is packaged in moisture-proof blister strips and should be stored below 25°C, protected from light and humidity.
In summary, Kureasia Pharma Apixaban 2.5 mg and 5 mg offer a modern, effective, and well-tolerated oral anticoagulant option designed for the prevention and treatment of thromboembolic disorders. Its targeted Factor Xa inhibition provides predictable anticoagulation, minimal food or drug interactions, and simplified therapy without the need for routine monitoring, making it a trusted and convenient choice in the management of cardiovascular and thrombotic conditions